Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Linda Röhner"'
Autor:
Edith Schneider, Anna Staffas, Linda Röhner, Erik D. Malmberg, Arghavan Ashouri, Kathrin Krowiorz, Nicole Pochert, Christina Miller, Stella Yuan Wei, Laleh Arabanian, Christian Buske, Hartmut Döhner, Lars Bullinger, Linda Fogelstrand, Michael Heuser, Konstanze Döhner, Ping Xiang, Jens Ruschmann, Oleh I. Petriv, Alireza Heravi-Moussavi, Carl L. Hansen, Martin Hirst, R. Keith Humphries, Arefeh Rouhi, Lars Palmqvist, Florian Kuchenbauer
Publikováno v:
Haematologica, Vol 103, Iss 2 (2018)
Micro-ribonucleic acid-155 (miR-155) is one of the first described oncogenic miRNAs. Although multiple direct targets of miR-155 have been identified, it is not clear how it contributes to the pathogenesis of acute myeloid leukemia. We found miR-155
Externí odkaz:
https://doaj.org/article/87401d72d1534be9b48a6f1e53390dbc
Autor:
Miriam Kull, Dirk Heckl, Martin Szyska, Denise Miller, Stephan R. Bohl, Lars Bullinger, Imke Bauhuf, Frederik Damm, Anthony Letai, Sarah Knödler, Christian Langer, Tamara J. Blätte, Jan Krönke, Anna Dolnik, Linda Röhner, Tatjana Meyer, Hartmut Döhner, Laura K. Schmalbrock
Publikováno v:
Blood Adv
The introduction of new drugs in the past years has substantially improved outcome in multiple myeloma (MM). However, the majority of patients eventually relapse and become resistant to one or multiple drugs. While the genetic landscape of relapsed/
Autor:
Linda Röhner, Andreas Beilhack, Annika Scheffold, Simon Köpff, Stefanie Lindner, Jan Krönke, Yuen Lam Dora Ng, Andreas Brandl
Publikováno v:
Experimental hematology. 93
The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide are approved drugs for the treatment of multiple myeloma. IMiDs induce cereblon (CRBN) E3 ubiquitin ligase-mediated ubiquitination and degradation of Ikaros transcription
Autor:
Michael Rehli, Steffen Stenger, Jan Krönke, Andrej Stoll, Heidi Balzer, Martin Busch, Maike Büttner-Herold, Claudia Gebhard, Simon Jitschin, Christopher Lischer, Andreas Mackensen, Martin Eberhardt, Simon Völkl, Martin Böttcher, Linda Röhner, Heiko Bruns, Fabian Beier, Mohamed H.S. Awwad, Michael Hundemer, Christian Bach, Christian Schütz, Dimitrios Mougiakakos, Magdalena Leffler, Katrin Bitterer, Julio Vera
Publikováno v:
Cancer immunology research. 9(3)
The bone marrow niche has a pivotal role in progression, survival, and drug resistance of multiple myeloma cells. Therefore, it is important to develop means for targeting the multiple myeloma bone marrow microenvironment. Myeloma-associated macropha
Autor:
Oleh Petriv, Jens Ruschmann, Edith Schneider, Lars Palmqvist, Kathrin Krowiorz, Anna Staffas, Erik Delsing Malmberg, Carl L. Hansen, Hartmut Döhner, Arefeh Rouhi, Florian Kuchenbauer, Martin Hirst, Arghavan Ashouri, Ping Xiang, Michael Heuser, Konstanze Döhner, Stella Yuan Wei, Lars Bullinger, Christina Miller, Linda Röhner, Nicole Pochert, R. Keith Humphries, Laleh S. Arabanian, Alireza Heravi-Moussavi, Christian Buske, Linda Fogelstrand
Publikováno v:
Haematologica
Micro-ribonucleic acid-155 (miR-155) is one of the first described oncogenic miRNAs. Although multiple direct targets of miR-155 have been identified, it is not clear how it contributes to the pathogenesis of acute myeloid leukemia. We found miR-155
Autor:
Annika Scheffold, Stefanie Lindner, Benjamin L. Ebert, Dirk Heckl, Linda Röhner, Daniela Weber, Peter Paschka, Jan Krönke, Anna Dolnik, Sebastian Wiese, Tatjana Meyer, Lars Bullinger, Hartmut Döhner, Konstanze Döhner, Verena I. Gaidzik, Nikolaus Jahn, Simon Köpff
Publikováno v:
Leukemia
BRCA1/BRCA2-containing complex 3 (BRCC3) is a Lysine 63-specific deubiquitinating enzyme (DUB) involved in inflammasome activity, interferon signaling, and DNA damage repair. Recurrent mutations in BRCC3 have been reported in myelodysplastic syndrome
Autor:
Michael Heuser, Lars Palmqvist, Florian Kuchenbauer, Arefeh Rouhi, Hartmut Döhner, Linda Röhner, Linda Fogelstrand, Edith Schneider, Konstanze Döhner, Anna Staffas
Publikováno v:
Blood. 126:2446-2446
Background: Genetic rearrangements that fuse the mixed lineage leukemia (MLL) gene, now termed KMT2A, to one of a variety of partners are seen in 5% - 20% of acute myeloid leukemia (AML). MLL -fusions are especially common in childhood AML and many o